omeprazole has been researched along with Atrophy in 17 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "Development of focal gland atrophy of the oxyntic mucosa was found in two patients with the Zollinger-Ellison syndrome undergoing long-term treatment with omeprazole." | 7.68 | Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment. ( Annibale, B; Azzoni, C; Bertelé, A; Bordi, C; Caruana, P; Delle Fave, G; Franzé, A, 1992) |
| "A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of gastric glandular atrophy in patients infected with Helicobacter pylori was investigated in this randomized study comparing omeprazole therapy with antireflux surgery (ARS) for chronic gastroesophageal reflux disease (GERD)." | 5.09 | Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. ( Andersson, A; Hattlebakk, J; Havu, N; Janatuinen, E; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K, 1999) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| " Oral administration of a proton pump inhibitor, omeprazole, which induced hypertrophy of the gastric mucosa with hypergastrinemia in wild-type littermates, did not eliminate the gastric atrophy of the homozygotes." | 3.69 | G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. ( Chihara, K; Ito, M; Iwata, N; Kuno, J; Matsui, T; Minowa, O; Nagata, A; Noda, T; Takano, H, 1996) |
| " Conversely, several studies have shown that long-term use of proton pump inhibitors is associated with progression and worsening of body gastritis exclusively in Helicobacter pylori-positives." | 2.40 | Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? ( Rauws, EA, 1997) |
| "Omeprazole-treated rats had significantly decreased the width of tight junction, villous length, and absorptive area of duodenum, jejunum, and ileum compared to control rats." | 1.62 | Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats. ( Chamniansawat, S; Kampuang, N; Suksridechacin, N; Thongon, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chamniansawat, S | 1 |
| Kampuang, N | 1 |
| Suksridechacin, N | 1 |
| Thongon, N | 1 |
| Kodama, M | 1 |
| Okimoto, T | 1 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 1 |
| Matsunari, O | 1 |
| Okamoto, K | 1 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 1 |
| Murakami, K | 1 |
| Waghray, M | 1 |
| Zavros, Y | 1 |
| Saqui-Salces, M | 1 |
| El-Zaatari, M | 1 |
| Alamelumangapuram, CB | 1 |
| Todisco, A | 1 |
| Eaton, KA | 1 |
| Merchant, JL | 1 |
| van Grieken, NC | 2 |
| Meijer, GA | 2 |
| Kale, I | 1 |
| Bloemena, E | 2 |
| Lindeman, J | 2 |
| Offerhaus, GJ | 1 |
| Meuwissen, SG | 2 |
| Baak, JP | 2 |
| Kuipers, EJ | 2 |
| Salih, BA | 1 |
| Abasiyanik, MF | 1 |
| Saribasak, H | 1 |
| Huten, O | 1 |
| Sander, E | 1 |
| Lundell, L | 2 |
| Havu, N | 2 |
| Miettinen, P | 2 |
| Myrvold, HE | 2 |
| Wallin, L | 1 |
| Julkunen, R | 1 |
| Levander, K | 2 |
| Hatlebakk, JG | 1 |
| Liedman, B | 2 |
| Lamm, M | 1 |
| Malm, A | 1 |
| Walan, A | 1 |
| Asaki, S | 1 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Nagata, A | 1 |
| Ito, M | 1 |
| Iwata, N | 1 |
| Kuno, J | 1 |
| Takano, H | 1 |
| Minowa, O | 1 |
| Chihara, K | 1 |
| Matsui, T | 1 |
| Noda, T | 1 |
| Tan, AC | 1 |
| den Hartog, G | 1 |
| Meijer, JW | 1 |
| Thies, JE | 1 |
| de Vries, RA | 1 |
| Mulder, CJ | 1 |
| Rauws, EA | 1 |
| Pedersen, SA | 1 |
| Thor, K | 1 |
| Andersson, A | 1 |
| Hattlebakk, J | 1 |
| Janatuinen, E | 1 |
| Nyström, P | 1 |
| Declich, P | 1 |
| Ambrosiani, L | 1 |
| Bellone, S | 1 |
| Tavani, E | 1 |
| Sung, JJ | 1 |
| Lin, SR | 1 |
| Ching, JY | 1 |
| Zhou, LY | 1 |
| To, KF | 1 |
| Wang, RT | 1 |
| Leung, WK | 1 |
| Ng, EK | 1 |
| Lau, JY | 1 |
| Lee, YT | 1 |
| Yeung, CK | 1 |
| Chao, W | 1 |
| Chung, SC | 1 |
| Weiss, MM | 1 |
| Caruana, P | 1 |
| Azzoni, C | 1 |
| Bertelé, A | 1 |
| Annibale, B | 1 |
| Franzé, A | 1 |
| Delle Fave, G | 1 |
| Bordi, C | 1 |
| Axelson, J | 1 |
| Håkanson, R | 1 |
| Sundler, F | 1 |
| Griffith, JL | 1 |
| Cummings, OW | 1 |
| Hirschowitz, BI | 1 |
1 review available for omeprazole and Atrophy
| Article | Year |
|---|---|
Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Topics: Anti-Ulcer Agents; Atrophy; Gastric Acid; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Helico | 1997 |
8 trials available for omeprazole and Atrophy
| Article | Year |
|---|---|
Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Endoscopy, Gastrointestinal; Gastric Muco | 2004 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Topics: Aged; Anti-Ulcer Agents; Atrophy; Enteroendocrine Cells; Female; Gastric Acid; Gastric Mucosa; Gastr | 2006 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
No additional value of bismuth subcitrate to combination omeprazole/amoxicillin therapy in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Data Interpreta | 1997 |
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Atrophy; Esophagitis; Female; Gastric Mucosa; Gastrins; | 1999 |
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Endoscopy; Female; Gastric | 2000 |
Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Enzyme Inhibitors; Female; Gastric M | 2001 |
8 other studies available for omeprazole and Atrophy
| Article | Year |
|---|---|
Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats.
Topics: Animals; Atrophy; Gastric Acid; Hypercalciuria; Inflammation; Intestinal Mucosa; Lymphocyte Activati | 2021 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
Interleukin-1beta promotes gastric atrophy through suppression of Sonic Hedgehog.
Topics: Animals; Atrophy; Calcium; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dogs; Epithe | 2010 |
G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo.
Topics: Animals; Atrophy; Chromaffin Cells; Chromogranin A; Chromogranins; DNA Probes; Gastric Mucosa; Gastr | 1996 |
Corpus-active gastritis with focal atrophy and parietal cell hyperplasia related to long-term use of omeprazole.
Topics: Atrophy; Gastritis; Humans; Hyperplasia; Omeprazole; Parietal Cells, Gastric; Stomach; Time Factors | 1999 |
Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment.
Topics: Adult; Atrophy; Endocrine Glands; Female; Humans; Hyperplasia; Male; Middle Aged; Omeprazole; Pariet | 1992 |
Antrectomy does not accelerate reversal of omeprazole-induced trophic effects in the rat stomach.
Topics: Animals; Atrophy; Cell Count; Cell Survival; Gastric Mucosa; Gastrins; Hyperplasia; Male; Omeprazole | 1992 |
Development of sustained achlorhydria in a patient with the Zollinger-Ellison syndrome treated with omeprazole.
Topics: Achlorhydria; Atrophy; Female; Gastric Mucosa; Humans; Middle Aged; Omeprazole; Zollinger-Ellison Sy | 1991 |